Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Ambrx Biopharma Inc - ADR before investing.

In this article, we go over a few key elements for understanding Ambrx Biopharma Inc - ADR’s stock price such as:

• Ambrx Biopharma Inc - ADR’s current stock price and volume
• Why Ambrx Biopharma Inc - ADR’s stock price changed recently
• Upgrades and downgrades for AMAM from analysts
• AMAM’s stock price momentum as measured by its relative strength

About Ambrx Biopharma Inc - ADR (AMAM)

Before we jump into Ambrx Biopharma Inc - ADR’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Ambrx Biopharma Inc. is a clinical-stage biologics company. It is focused on discovering and developing a novel class of engineered precision biologics, using its expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids (SAAs), into proteins within living cells. Its product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation, offering potential safety and benefits to treat patients across multiple therapeutic areas. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as antibody-drug conjugates (ADCs), immuno-oncology conjugate, bispecific antibodies, PEGylated peptides, modified cytokines and immuno-stimulating antibody conjugates. Its lead ADC product candidates in clinical development: ARX788 and ARX517. ARX517 is an anti-prostate-specific membrane antigen.

Want to learn more about Ambrx Biopharma Inc - ADR’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ambrx Biopharma Inc - ADR.

Ambrx Biopharma Inc - ADR’s Stock Price as of Market Close

As of September 22, 2023, 4:00 PM, CST, Ambrx Biopharma Inc - ADR’s stock price was $11.32.

Ambrx Biopharma Inc - ADR is down 4.39% from its previous closing price of $11.84.

During the last market session, Ambrx Biopharma Inc - ADR’s stock traded between $11.19 and $12.05. Currently, there are 55.90 million shares of Ambrx Biopharma Inc - ADR stock available for purchase.

Unfortunately, Ambrx Biopharma Inc - ADR’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Ambrx Biopharma Inc - ADR Stock Price History

Ambrx Biopharma Inc - ADR’s (AMAM) price is currently down 19.83% so far this month.

During the month of September, Ambrx Biopharma Inc - ADR’s stock price has reached a high of $15.10 and a low of $8.33.

Over the last year, Ambrx Biopharma Inc - ADR has hit prices as high as $16.86 and as low as $0.38. Year to date, Ambrx Biopharma Inc - ADR’s stock is up 25.36%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Ambrx Biopharma Inc - ADR Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 21, 2023, there were 0 analysts who downgraded Ambrx Biopharma Inc - ADR’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Ambrx Biopharma Inc - ADR’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Ambrx Biopharma Inc - ADR’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ambrx Biopharma Inc - ADR (AMAM) by visiting AAII Stock Evaluator.

Relative Price Strength of Ambrx Biopharma Inc - ADR

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 21, 2023, Ambrx Biopharma Inc - ADR has a weighted four-quarter relative price strength of 82.57%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how Ambrx Biopharma Inc - ADR is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Ambrx Biopharma Inc - ADR Stock Price: Bottom Line

As of September 22, 2023, Ambrx Biopharma Inc - ADR’s stock price is $11.32, which is down 4.39% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Ambrx Biopharma Inc - ADR stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.